FibroGen (Mexico) Insiders
FGEN Stock | MXN 8.72 0.26 2.90% |
FibroGen employs about 566 people. The company is managed by 10 executives with a total tenure of roughly 1321 years, averaging almost 132.0 years of service per executive, having 56.6 employees per reported executive. Break down of FibroGen's management performance can provide insight into the company performance.
Mr JD Insider Chief Officer |
Enrique Conterno Insider CEO Director |
FibroGen |
FibroGen Management Team Effectiveness
The company has return on total asset (ROA) of (0.2656) % which means that it has lost $0.2656 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.8478) %, meaning that it generated substantial loss on money invested by shareholders. FibroGen's management efficiency ratios could be used to measure how well FibroGen manages its routine affairs as well as how well it operates its assets and liabilities.FibroGen Workforce Comparison
FibroGen is one of the top stocks in number of employees category among its peers. The total workforce of Biotechnology industry is currently estimated at about 120,589. FibroGen adds roughly 566 in number of employees claiming only tiny portion of stocks in Biotechnology industry.
The company has Profit Margin (PM) of (2.94) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (2.52) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $2.52. FibroGen Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. FibroGen Price Series Summation is a cross summation of FibroGen price series and its benchmark/peer.
FibroGen Notable Stakeholders
A FibroGen stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as FibroGen often face trade-offs trying to please all of them. FibroGen's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting FibroGen's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Mr JD | Chief Officer | Profile | |
Enrique Conterno | CEO Director | Profile | |
Barry Berkowitz | Founder | Profile | |
Christine Chung | VP Operations | Profile | |
Elias Kouchakji | Drug Devel | Profile | |
Juan Graham | Chief Officer | Profile | |
Karen Bergman | VP Communications | Profile | |
Thane Wettig | Ex Officer | Profile | |
MPH MD | Ex Officer | Profile | |
John Hunter | Chief Officer | Profile |
About FibroGen Management Performance
The success or failure of an entity such as FibroGen often depends on how effective the management is. FibroGen management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of FibroGen management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the FibroGen management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company was incorporated in 1993 and is headquartered in San Francisco, California. FibroGen operates under Biotechnology classification in Mexico and is traded on Mexico Stock Exchange. It employs 461 people.
Please note, the imprecision that can be found in FibroGen's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of FibroGen. Check FibroGen's Beneish M Score to see the likelihood of FibroGen's management manipulating its earnings.
FibroGen Workforce Analysis
Traditionally, organizations such as FibroGen use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare FibroGen within its industry.FibroGen Manpower Efficiency
Return on FibroGen Manpower
Revenue Per Employee | 415.7K | |
Revenue Per Executive | 23.5M | |
Net Loss Per Employee | 512.4K | |
Net Loss Per Executive | 29M |
Additional Tools for FibroGen Stock Analysis
When running FibroGen's price analysis, check to measure FibroGen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy FibroGen is operating at the current time. Most of FibroGen's value examination focuses on studying past and present price action to predict the probability of FibroGen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move FibroGen's price. Additionally, you may evaluate how the addition of FibroGen to your portfolios can decrease your overall portfolio volatility.